Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma
- Kuang Du
- Shiyou Wei
- Zhi Wei
- Dennie T. Frederick
- Benchun Miao
- Tabea Moll
- Tian Tian
- Eric Sugarman
- Dmitry I. Gabrilovich
- Ryan J. Sullivan
- Lunxu Liu
- Keith T. Flaherty
- Genevieve M. Boland
- Meenhard Herlyn
- Gao Zhang
Publication date
October 2021
DOI Publisher
Springer Science and Business Media LLC Journal
Nature CommunicationsAbstract
Gene signatures that predict response to immune checkpoint blockade (ICB) therapies in melanoma have been based on preclinical models and pre-treatment samples. Here the authors develop pathway-based signatures to predict ICB response in melanoma using on-treatment samples, leading to improved performance
Add to ORKG
